Quarterly report · Q3

Period2022-04-01 → 2022-12-31
Filed2023-02-10
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥175.2bn2022-04-01 → 2022-12-31Cons.Revenue IFRS
Revenue¥62.5bn2022-10-01 → 2022-12-31dCons.Revenue IFRS
Revenue¥208.2bn2021-04-01 → 2022-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥154.2bn2021-04-01 → 2021-12-31Cons.Revenue IFRS
Revenue¥56.5bn2021-10-01 → 2021-12-31dCons.Revenue IFRS
Operating income¥58.7bn2022-04-01 → 2022-12-31Cons.Operating profit loss IFRS
Operating income¥22.4bn2022-10-01 → 2022-12-31dCons.Operating profit loss IFRS
Operating income¥84.6bn2021-04-01 → 2021-12-31Cons.Operating profit loss IFRS
Operating income¥22.7bn2021-10-01 → 2021-12-31dCons.Operating profit loss IFRS
Profit before tax¥60.2bn2022-04-01 → 2022-12-31Cons.Profit loss before tax IFRS
Profit before tax¥22.2bn2022-10-01 → 2022-12-31dCons.Profit loss before tax IFRS
Profit before tax¥96.2bn2021-04-01 → 2022-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥85.2bn2021-04-01 → 2021-12-31Cons.Profit loss before tax IFRS
Profit before tax¥22.9bn2021-10-01 → 2021-12-31dCons.Profit loss before tax IFRS
Net income (owners)¥39.3bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥15.2bn2022-10-01 → 2022-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥63.8bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥56.2bn2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥15.4bn2021-10-01 → 2021-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income¥41.8bn2022-04-01 → 2022-12-31Cons.Profit loss IFRS
Net income¥15.9bn2022-10-01 → 2022-12-31dCons.Profit loss IFRS
Net income¥58.5bn2021-04-01 → 2021-12-31Cons.Profit loss IFRS
Net income¥15.8bn2021-10-01 → 2021-12-31dCons.Profit loss IFRS
Total assets¥380.7bnat 2022-12-31Cons.Assets IFRS
Total assets¥346.0bnat 2022-03-31Cons.Assets IFRS
Total assets¥324.8bnat 2021-12-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥83.4bnat 2022-12-31Cons.Liabilities IFRS
Total liabilities¥82.0bnat 2022-03-31Cons.Liabilities IFRS
Net assets / equity¥297.4bnat 2022-12-31Cons.Equity IFRS
Net assets / equity¥264.0bnat 2022-03-31Cons.Equity IFRS
Net assets / equity¥252.7bnat 2021-12-31Cons.Equity IFRS
Net assets / equity¥207.3bnat 2021-03-31dCons.Equity IFRS
Equity (owners)¥290.7bnat 2022-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥257.8bnat 2022-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥246.6bnat 2021-12-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥109.8bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥104.3bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥95.3bnat 2021-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥89.1bnat 2021-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥33.4bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥52.1bn2021-04-01 → 2022-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥31.0bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥8.6bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥23.4bn2021-04-01 → 2022-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥10.1bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥20.7bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥16.4bn2021-04-01 → 2022-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥15.6bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥57.862022-04-01 → 2022-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥22.422022-10-01 → 2022-12-31dCons.Basic earnings loss per share IFRS
EPS (basic)¥94.062021-04-01 → 2022-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥82.752021-04-01 → 2021-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥22.662021-10-01 → 2021-12-31dCons.Basic earnings loss per share IFRS
EPS (diluted)¥57.822022-04-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥22.42022-10-01 → 2022-12-31dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥93.982021-04-01 → 2022-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥82.682021-04-01 → 2021-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥22.642021-10-01 → 2021-12-31dCons.Diluted earnings loss per share IFRS
Equity ratio76.4%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio74.5%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio75.9%at 2021-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 107
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥3.9bn
Reconciling Itemsreconcilingrevenue2022-10-01 → 2022-12-31−¥1.1bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥3.9bn
Reconciling Itemsreconcilingrevenue intersegment2022-10-01 → 2022-12-31−¥1.1bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥1.1bn
Reconciling Itemsreconcilingsegment profit2022-10-01 → 2022-12-31−¥418m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue2022-04-01 → 2022-12-31¥11.5bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue2022-10-01 → 2022-12-31¥3.1bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue external2022-04-01 → 2022-12-31¥10.8bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue external2022-10-01 → 2022-12-31¥2.9bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥623m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥178m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentsegment profit2022-04-01 → 2022-12-31¥4.2bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentsegment profit2022-10-01 → 2022-12-31¥734m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue2022-04-01 → 2022-12-31¥20.6bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue2022-10-01 → 2022-12-31¥6.6bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue external2022-04-01 → 2022-12-31¥20.1bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue external2022-10-01 → 2022-12-31¥6.4bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥521m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥174m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentsegment profit2022-04-01 → 2022-12-31¥6.0bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentsegment profit2022-10-01 → 2022-12-31¥1.8bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue2022-04-01 → 2022-12-31¥69.8bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue2022-10-01 → 2022-12-31¥27.2bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue external2022-04-01 → 2022-12-31¥67.4bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue external2022-10-01 → 2022-12-31¥26.5bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥2.4bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥739m
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentsegment profit2022-04-01 → 2022-12-31¥32.1bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentsegment profit2022-10-01 → 2022-12-31¥13.3bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue2022-04-01 → 2022-12-31¥47.3bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue2022-10-01 → 2022-12-31¥17.1bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue external2022-04-01 → 2022-12-31¥47.2bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue external2022-10-01 → 2022-12-31¥17.1bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥21m
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥17m
jpcrp040300-q3r_E05425-000Overseasreportable segmentsegment profit2022-04-01 → 2022-12-31¥13.9bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentsegment profit2022-10-01 → 2022-12-31¥5.8bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue2022-04-01 → 2022-12-31¥27.5bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue2022-10-01 → 2022-12-31¥8.8bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue external2022-04-01 → 2022-12-31¥27.2bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue external2022-10-01 → 2022-12-31¥8.8bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥304m
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentsegment profit2022-04-01 → 2022-12-31¥3.2bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentsegment profit2022-10-01 → 2022-12-31¥917m
—segment totalrevenue2022-04-01 → 2022-12-31¥176.6bn
—segment totalrevenue2022-10-01 → 2022-12-31¥62.7bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥172.8bn
—segment totalrevenue external2022-10-01 → 2022-12-31¥61.6bn
—segment totalrevenue intersegment2022-04-01 → 2022-12-31¥3.8bn
—segment totalrevenue intersegment2022-10-01 → 2022-12-31¥1.1bn
—segment totalsegment profit2022-04-01 → 2022-12-31¥59.5bn
—segment totalsegment profit2022-10-01 → 2022-12-31¥22.6bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-12-31−¥3.7bn
Reconciling Itemsreconcilingrevenue2021-10-01 → 2021-12-31−¥1.2bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-12-31−¥3.7bn
Reconciling Itemsreconcilingrevenue intersegment2021-10-01 → 2021-12-31−¥1.2bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-12-31−¥1.3bn
Reconciling Itemsreconcilingsegment profit2021-10-01 → 2021-12-31−¥803m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue2021-04-01 → 2021-12-31¥11.0bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue2021-10-01 → 2021-12-31¥2.8bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue external2021-04-01 → 2021-12-31¥10.6bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue external2021-10-01 → 2021-12-31¥2.7bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥465m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue intersegment2021-10-01 → 2021-12-31¥102m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentsegment profit2021-04-01 → 2021-12-31¥4.0bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentsegment profit2021-10-01 → 2021-12-31¥582m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue2021-04-01 → 2021-12-31¥16.2bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue2021-10-01 → 2021-12-31¥6.1bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue external2021-04-01 → 2021-12-31¥15.5bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue external2021-10-01 → 2021-12-31¥5.8bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥710m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2021-10-01 → 2021-12-31¥227m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentsegment profit2021-04-01 → 2021-12-31¥3.8bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentsegment profit2021-10-01 → 2021-12-31¥1.8bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue2021-04-01 → 2021-12-31¥64.7bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue2021-10-01 → 2021-12-31¥26.3bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue external2021-04-01 → 2021-12-31¥62.7bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue external2021-10-01 → 2021-12-31¥25.6bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥2.0bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue intersegment2021-10-01 → 2021-12-31¥674m
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentsegment profit2021-04-01 → 2021-12-31¥30.8bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentsegment profit2021-10-01 → 2021-12-31¥14.1bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue2021-04-01 → 2021-12-31¥37.9bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue2021-10-01 → 2021-12-31¥13.5bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue external2021-04-01 → 2021-12-31¥37.8bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue external2021-10-01 → 2021-12-31¥13.5bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥17m
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue intersegment2021-10-01 → 2021-12-31¥5m
jpcrp040300-q3r_E05425-000Overseasreportable segmentsegment profit2021-04-01 → 2021-12-31¥41.5bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentsegment profit2021-10-01 → 2021-12-31¥3.4bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue2021-04-01 → 2021-12-31¥25.7bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue2021-10-01 → 2021-12-31¥8.2bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue external2021-04-01 → 2021-12-31¥25.2bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue external2021-10-01 → 2021-12-31¥8.0bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥438m
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue intersegment2021-10-01 → 2021-12-31¥200m
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentsegment profit2021-04-01 → 2021-12-31¥4.6bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentsegment profit2021-10-01 → 2021-12-31¥2.0bn
—segment totalrevenue2021-04-01 → 2021-12-31¥155.4bn
—segment totalrevenue2021-10-01 → 2021-12-31¥56.8bn
—segment totalrevenue external2021-04-01 → 2021-12-31¥151.8bn
—segment totalrevenue external2021-10-01 → 2021-12-31¥55.6bn
—segment totalrevenue intersegment2021-04-01 → 2021-12-31¥3.6bn
—segment totalrevenue intersegment2021-10-01 → 2021-12-31¥1.2bn
—segment totalsegment profit2021-04-01 → 2021-12-31¥84.7bn
—segment totalsegment profit2021-10-01 → 2021-12-31¥21.8bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 789
ItemContextValueUnit
Company name cover pageFilingDateInstant
Original text (Japanese)エムスリー株式会社
Company name in english cover pageFilingDateInstantM3, Inc.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長  谷 村   格
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都港区赤坂一丁目11番44号
Telephone number address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)03(6229)8900(代表)
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)取締役      槌 屋   英 二
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都港区赤坂一丁目11番44号
Telephone number nearest place of contact cover pageFilingDateInstant
Original text (Japanese)03(6229)8900(代表)
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)取締役      槌 屋   英 二
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE05425
Fund codeFilingDateInstant-
Security codeFilingDateInstant24130
Filer name in japaneseFilingDateInstant
Original text (Japanese)エムスリー株式会社
Filer name in englishFilingDateInstantM3, Inc.
Fund name in japaneseFilingDateInstant-
Fund name in englishFilingDateInstant-
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令
Document typeFilingDateInstant
Original text (Japanese)第四号の三様式
Accounting standardsFilingDateInstantIFRS
Whether consolidated financial statements are preparedFilingDateInstanttrue
Industry code when consolidated financial statements are prepared in accordance with industry specific regulationsFilingDateInstantCTE
Industry code when financial statements are prepared in accordance with industry specific regulationsFilingDateInstant-
Current fiscal year start dateFilingDateInstant2022-04-01
Current period end dateFilingDateInstant2022-12-31
Type of current periodFilingDateInstantQ3
Current fiscal year end dateFilingDateInstant2023-03-31
Previous fiscal year start dateFilingDateInstant2021-04-01
Comparative period end dateFilingDateInstant2021-12-31
Previous fiscal year end dateFilingDateInstant2022-03-31
Next fiscal year start dateFilingDateInstant-
End date of quarterly or semi annual period of next fiscal yearFilingDateInstant-
Amendment flagFilingDateInstantfalse
Identification of document subject to amendmentFilingDateInstant-
Report amendment flagFilingDateInstantfalse
Xbrl amendment flagFilingDateInstantfalse
Business results of group (text)FilingDateInstantText · Plus
Description of business (text)FilingDateInstantText · Plus
Business risks (text)FilingDateInstantText · Plus
Management analysis of financial position operating results and cash flows (text)FilingDateInstantText · Plus
Critical contracts for operation (text)FilingDateInstantText · Plus
Total number of shares (text)FilingDateInstantText · Plus
Issued shares total number of shares etc (text)FilingDateInstantText · Plus
Class issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember
Original text (Japanese)普通株式
Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registeredFilingDateInstant_OrdinaryShareMember
Original text (Japanese)東京証券取引所プライム市場
Description issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember
Original text (Japanese)単元株式数100株
Details of employee share option program (text)FilingDateInstantText · Plus
Other information on share acquisition rights (text)FilingDateInstantText · Plus
Exercises etc of moving strike convertible bonds etc (text)FilingDateInstantText · Plus
Changes in number of issued shares stated capital etc (text)FilingDateInstantText · Plus

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-10-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-10-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-12-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-04-01/2021-12-31pass
statement vs summary · revenueconsolidated 2021-10-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2022-10-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass